دورية أكاديمية
MRI-guided percutaneous thermoablation as first-line treatment of recurrent hepatic malignancies following hepatic resection: single center long-term experience
| العنوان: | MRI-guided percutaneous thermoablation as first-line treatment of recurrent hepatic malignancies following hepatic resection: single center long-term experience |
|---|---|
| المؤلفون: | G. Gohla, R. Archid, R. Hoffmann, J. Kübler, M. Munzel, A. Königsrainer, S. Nadalin, K. Nikolaou, M. T. Winkelmann |
| المصدر: | International Journal of Hyperthermia, Vol 38, Iss 1, Pp 1401-1408 (2021) |
| بيانات النشر: | Taylor & Francis Group, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Medical technology |
| مصطلحات موضوعية: | microwave ablation, magnetic resonance imaging, liver tumors, tumor ablation, hepatic malignancies, Medical technology, R855-855.5 |
| الوصف: | Purpose Hepatic recurrence of liver malignancies is a leading problem in patients after liver resection with curative intention. Thermoablation is a promising treatment approach for patients after hepatic resection, especially in liver-limited conditions. This study aimed to investigate safety, survival, and local tumor control rates of MRI-guided percutaneous thermoablation of recurrent hepatic malignancies following hepatic resection. Material and methods Data from patients with primary or secondary hepatic malignancies treated between 2004 and 2018 with MRI-guided percutaneous thermoablation of hepatic recurrence after prior hepatic resection were retrospectively analyzed. Disease-free survival and overall survival rates were calculated using the Kaplan-Meier method. Results A total of 57 patients with hepatic recurrence (mean tumor size = 18.9 ± 9.1 mm) of colorectal cancer liver metastases (n = 27), hepatocellular carcinoma (n = 17), intrahepatic recurrence of cholangiocellular carcinoma (n = 9), or other primary malignant tumor entities (n = 4) were treated once or several times with MR-guided percutaneous radiofrequency (n = 52) or microwave ablation (n = 5) (range: 1–4 times). Disease progression occurred due to local recurrence at the ablation site in nine patients (15.8%), non-local hepatic recurrence in 33 patients (57.9%), and distant malignancy in 18 patients (31.6%). The median overall survival for the total cohort was 40 months and 49 months for the colorectal cancer group, with a 5-year overall survival rate of 40.7 and 42.5%, respectively. The median disease-free survival was 10 months for both the total cohort and the colorectal cancer group with a 5-year disease-free survival rate of 15.1 and 14.8%, respectively. The mean follow-up time was 39.6 ± 35.7 months. Conclusion MR-guided thermoablation is an effective and safe approach in the treatment of hepatic recurrences in liver-limited conditions and can achieve long-term survival. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 0265-6736 1464-5157 02656736 |
| Relation: | https://doaj.org/toc/0265-6736; https://doaj.org/toc/1464-5157 |
| DOI: | 10.1080/02656736.2021.1979257 |
| URL الوصول: | https://doaj.org/article/a522949165534213bc07d8cf4d34cf29 |
| رقم الأكسشن: | edsdoj.522949165534213bc07d8cf4d34cf29 |
| قاعدة البيانات: | Directory of Open Access Journals |
PDF full text from Publisher 
Full Text Finder | تدمد: | 02656736 14645157 |
|---|---|
| DOI: | 10.1080/02656736.2021.1979257 |